Abstract
Hepatic fibrogenesis is a complex process that is driven by activated hepatic stellate cells as part of the liver's normal wound healing response. These cells drive the process through matrix production, cytokine secretion, and immune and other cell-cell interactions. Ultimately, fibrosis accumulates when matrix production outpaces matrix degradation. This chapter explores the complex interplay of genetic, environmental, and social factors on the progression of fibrosis. Furthermore, it assesses the efficacy and limitations of non-invasive markers for fibrosis staging and highlights the pressing need for more accurate markers linked to clinically meaningful outcomes. This need is particularly urgent for the development of antifibrotic treatments, especially for conditions like metabolic dysfunction-associated steatohepatitis (MASH), to improve patient management and therapeutic success.
Original language | English |
---|---|
Title of host publication | Hepatology |
Subtitle of host publication | an Evidence-Based Clinical Compendium: Volume 1-2 |
Publisher | Elsevier |
Pages | 247-272 |
Number of pages | 26 |
Volume | 1-2 |
ISBN (Electronic) | 9780443300523 |
ISBN (Print) | 9780443300530 |
DOIs | |
State | Published - 1 Jan 2024 |
Keywords
- Antifibrotic therapies
- Fibrogenesis
- Hepatic stellate cells
- Liver fibrosis
- Non-invasive markers